IDEXX Laboratories enters its August 7 earnings report with options traders notably more defensive than they have been all year, even as the stock has quietly gained ground over the past month.
The clearest tension in the data is in options positioning. The put/call ratio has jumped to 0.72, running more than two standard deviations above its 20-day average of 0.51 — the most bearish skew seen outside of last year's extremes. That shift happened abruptly: for most of July, the PCR sat in a narrow band around 0.45–0.48. The move higher began in earnest on August 3–4, suggesting this is directly earnings-driven hedging rather than a slow drift. Against that, the stock itself has held up reasonably well, gaining 4.8% over the past month to $584.78, with a modest 0.6% dip on Wednesday.
The lending market tells a completely different story — bears have no structural foothold here. Borrow availability is extraordinarily loose, with over 56 million shares available relative to roughly 2 million shorted. Short interest has declined 11% over the past month to 2.5% of the float, and cost to borrow has eased nearly 20% on the week to 0.45%. This is not a stock the short-selling community is pressing into the print.
Analysts who have moved most recently have been constructive. UBS and Citigroup both raised price targets on August 5 — just ahead of the report — to $670, compared to their prior levels of $620 and $650 respectively. That said, both firms hold Neutral ratings, so the upgrades reflect reduced pessimism rather than conviction buying. The consensus sits at buy with a mean target of $705.85, implying roughly 21% upside from current levels. The bull case centres on IDEXX's recurring revenue base — its instrument consumables and diagnostic subscription model — and the durable "humanization of pets" tailwind. The bear case is narrower: potential supply chain friction and the ceiling on valuation, with a P/E near 35x that leaves little room for a guidance miss. A recent ORTEX note flagged stronger-than-expected Q2 diagnostics revenue and a 2.3% stock lift when initial Q2 data hit on August 3–4, which may partly explain why UBS and Citi moved their targets before the formal print.
The formal August 7 report will test whether IDEXX can sustain the margin expansion and international growth that underpinned that early read — and whether a stock trading at a meaningful premium to the Street's targets can hold its gains if guidance lands below the more optimistic end of analyst expectations.
See the live data behind this article on ORTEX.
Open IDXX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
